Publications
- Daratumumab with lenalidomide and dexamethasone in relapsed or refractory multiple myeloma patients – real world evidence analysis2023 | First Faculty of Medicine, Central Library of Charles University, Faculty of Medicine in Hradec Králové
- Personalised progression prediction in patients with monoclonal gammopathy of undetermined significance or smouldering multiple myeloma (PANGEA): a retrospective, multicohort study2023 | First Faculty of Medicine, Faculty of Medicine in Hradec Králové
- Patient Characteristics, Treatment Patterns, and Outcomes in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma Patients, a Retrospective Observational Study Using Czech2023 | First Faculty of Medicine, Faculty of Medicine in Hradec Králové
- Determinants of refined GvHD-free, relapse-free survival after reduced-intensity allogeneic hematopoietic cell transplantation in older patients with myeloid malignancies2023 | Faculty of Medicine in Pilsen
- Allogeneic stem cell transplantation in patients with multiple myeloma-single center experience2023 | Publication without faculty affiliation
- Real-world evidence of efficacy and safety of pomalidomide and dexamethasone in relapsed/refractory multiple myeloma patients: Czech registry data2022 | First Faculty of Medicine, Faculty of Medicine in Pilsen, Central Library of Charles University, Faculty of Medicine in Hradec Králové, Third Faculty of Medicine
- Identification of patients at high risk of secondary extramedullary multiple myeloma development2022 | First Faculty of Medicine, Central Library of Charles University, Faculty of Medicine in Hradec Králové
- Ixazomib, Lenalidomide and Dexamethasone in Relapsed and Refractory Multiple Myeloma in Routine Clinical Practice: Extended Follow-Up Analysis and the Results of Subsequent Therapy2022 | First Faculty of Medicine, Faculty of Medicine in Hradec Králové, Third Faculty of Medicine
- Mutation landscape of multiple myeloma measurable residual disease: identification of targets for precision medicine2022 | Publication without faculty affiliation
- Survival benefit of ixazomib, lenalidomide and dexamethasone (IRD) over lenalidomide and dexamethasone (Rd) in relapsed and refractory multiple myeloma patients in routine clinical practice2021 | First Faculty of Medicine, Faculty of Medicine in Hradec Králové, Third Faculty of Medicine
Loading network view...